Insights - Bellus (BLU) is up over 10% this morning on news that Merck’s Phase 3 candidate gefapixant met efficacy endpoints in chronic cough (read here). Merck … Continue Reading
Read nowInsights - We think there are some solid value plays with the current market rout. We’re looking at companies with enough cash to weather the storm and … Continue Reading
PremiumInsights - Fennec announced that the US Patent & Trademark Office will issue U.S. Patent 10,596,190 to Pedmark. The patent is titled “Method for Reducing Ototoxicity in Pediatric Patients … Continue Reading
Read nowInsights - Stemline’s FDA approved product is targeting a newly classified ultra-orphan indication called BPDCN. There is no other approved products in this indication. The company is … Continue Reading
PremiumInterviews - PropThink interviewed Dr. CJ Barnum to get his insights on the current state of Alzheimer’s and the neuro-inflammation approach, one of the emerging research strategies. … Continue Reading
Read nowInsights - This morning Fennec (FENC) announced that the company completed their NDA filing to FDA & application to EMA (read here). Surprising EMA SubmissionEuropean submission was a pleasant surprise, as … Continue Reading
PremiumInterviews - The shortcomings of Alzheimer’s research stems from a fundamental belief that removing amyloid is the treatment approach. The research community has been led astray by … Continue Reading
Read now
